MedPath

GM3 and insulin sensitivity.

Conditions
Diabetes, obesity, insulin resistance,
Registration Number
NL-OMON21599
Lead Sponsor
Academic Medical Center (AMC), Department of Endocrinology and Metabolism
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

Inclusion criteria for all participants

1. Written informed consent

Exclusion Criteria

Exclusion criteria for all participants:

1. Participation in an investigational drug trial within 90 days prior to our study

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
- Peripheral glucose uptake (Rd)<br /><br>- Ganglisosides concentration in muscle and adipose tissue<br>
Secondary Outcome Measures
NameTimeMethod
- Plasma concentration of glucoregulatory hormones<br /><br>- Energy expenditure<br /><br>- Carbohydrate oxidation and fat oxidation<br /><br>- VO2 max<br /><br>- Muscle fiber type<br /><br>
© Copyright 2025. All Rights Reserved by MedPath